Candel Therapeutics, Inc. - Common Stock, $0.01 par value (CADL)
CUSIP: 137404109
Q1 2024 13F Holders as of 31 Mar 2024
- Type / Class
- Equity / Common Stock, $0.01 par value
- Shares outstanding
- 72,977,477
- Total 13F shares
- 3,780,257
- Share change
- -169,992
- Total reported value
- $5,972,529
- Price per share
- $1.58
- Number of holders
- 18
- Value change
- -$231,572
- Number of buys
- 9
- Number of sells
- 10
Quarterly Holders Quick Answers
What is CUSIP 137404109?
CUSIP 137404109 identifies CADL - Candel Therapeutics, Inc. - Common Stock, $0.01 par value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 137404109:
Top shareholders of CADL - Candel Therapeutics, Inc. - Common Stock, $0.01 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Northpond Ventures, LLC |
13F
|
Company |
2.7%
|
1,935,215
|
$2,844,766 | — | 31 Dec 2023 | |
| Laura K. Aguilar |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
3,046,940
|
$2,742,246 | — | 06 May 2022 | |
| Sands Capital Alternatives, LLC |
13F
|
Company |
1.1%
|
811,737
|
$1,193,253 | — | 31 Dec 2023 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.58%
|
425,749
|
$625,851 | — | 31 Dec 2023 | |
| FMR LLC |
13F
|
Company |
0.41%
|
298,384
|
$438,624 | — | 31 Dec 2023 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.19%
|
139,253
|
$204,737 | — | 31 Dec 2023 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.18%
|
132,595
|
$194,915 | — | 31 Dec 2023 | |
| Jason Amello |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
292,009
mixed-class rows
|
$181,808 | — | 28 Nov 2023 | |
| Baystate Wealth Management LLC |
13F
|
Company |
0.11%
|
76,910
|
$113,058 | — | 31 Dec 2023 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.07%
|
49,285
|
$72,450 | — | 31 Dec 2023 | |
| Udi Meirav |
3/4/5
|
Director |
—
class O/S missing
|
48,822
|
$43,940 | — | 26 Jul 2021 | |
| OneDigital Investment Advisors LLC |
13F
|
Company |
0.04%
|
29,783
|
$43,781 | — | 31 Dec 2023 | |
| STATE STREET CORP |
13F
|
Company |
0.04%
|
27,600
|
$40,572 | — | 31 Dec 2023 | |
| SMITH ALAN E |
3/4/5
|
Director |
—
class O/S missing
|
32,548
|
$29,293 | — | 26 Jul 2021 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.03%
|
19,617
|
$28,837 | — | 31 Dec 2023 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.03%
|
18,675
|
$27,000 | — | 31 Dec 2023 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.02%
|
16,852
|
$24,772 | — | 31 Dec 2023 | |
| TWO SIGMA SECURITIES, LLC |
13F
|
Company |
0.02%
|
16,510
|
$24,270 | — | 31 Dec 2023 | |
| UBS Group AG |
13F
|
Company |
0.02%
|
11,921
|
$17,524 | — | 31 Dec 2023 | |
| Vontobel Holding Ltd. |
13F
|
Company |
0.01%
|
10,000
|
$14,696 | — | 31 Dec 2023 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.01%
|
6,733
|
$9,898 | — | 31 Dec 2023 | |
| Nathan Caffo |
3/4/5
|
Chief Business Officer |
—
class O/S missing
|
6,000
|
$5,400 | — | 29 Jul 2021 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
209
|
$307 | — | 31 Dec 2023 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
113
|
$166 | — | 31 Dec 2023 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
18
|
$26 | — | 31 Dec 2023 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0%
|
1
|
$1 | — | 31 Dec 2023 | |
| John J. Canepa |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
110,000
|
— | — | 28 Feb 2022 | |
| Susan B. Stewart |
3/4/5
|
Chief Regulatory Officer |
—
class O/S missing
|
20,000
|
— | — | 11 Apr 2022 |
Institutional Holders of Candel Therapeutics, Inc. - Common Stock, $0.01 par value (CADL) as of Q1 2024
As of 31 Mar 2024,
Candel Therapeutics, Inc. - Common Stock, $0.01 par value (CADL) was held by
18 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,780,257 shares.
The largest 10 holders included
Northpond Ventures, LLC, Sands Capital Ventures, LLC, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, BRIDGEWAY CAPITAL MANAGEMENT, LLC, RENAISSANCE TECHNOLOGIES LLC, BlackRock Inc., Mariner, LLC, OneDigital Investment Advisors LLC, and STATE STREET CORP.
This page lists
18
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2024 vs Q4 2023 Across Filers
Q4 2023 holders
21
Q1 2024 holders
18
Holder diff
-3
| Investor | Q4 2023 Shares | Q1 2024 Shares | Share Diff | Share Chg % | Q4 2023 Value $ | Q1 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.